Patents by Inventor Mutsuo Taiji
Mutsuo Taiji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050227978Abstract: Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2): (1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 28, 2003Publication date: October 13, 2005Applicant: Sumitomo Pharmaceuticals Co., Ltd.Inventors: Teruhisa Tokunaga, Willian Hume, Makoto Kitoh, Ryu Nagata, Michiko Kishino, Tsutomu Nakagawa, Jun Nagamine, Mutsuo Taiji
-
Publication number: 20050119174Abstract: The present invention provides an impaired glucose tolerance ameliorating drug and a therapeutic drug for lifestyle-related diseases, particular an antidiabetic drug, which contain a CXCR3 agonist as an active ingredient; a hypoglycemia ameliorating drug, a therapeutic drug for insulinoma or an anti-obesity drug containing a CXCR3 antagonist as an active ingredient; a method of screening for a new CXCR3 ligand using CXCR3 and a known CXCR3 ligand; a method of screening a CXCR3 ligand, which uses a co-expression system of CXCR3 and a coupling G protein; and a diagnostic method for type II diabetes, which includes detecting an amount of a CXCR3 ligand expressed in a biological sample.Type: ApplicationFiled: April 3, 2003Publication date: June 2, 2005Applicant: Sumitomo Pharmaceuticals Co. Ltd.Inventors: Eiji Sugaru, Junji Ichihara, Mutsuo Taiji
-
Patent number: 6887477Abstract: Preparations to be administered for treating or preventing ischemic diseases or arterial diseases which contain Hepatocyte growth factor (HGF) as an active ingredient. The preparations provide such effect that HGF concentration in an affected region to which HGF was administered is maintained, a half-life is longer, a dose can be reduced, and other organs except the affected region are less affected in comparison with intravenous administration.Type: GrantFiled: August 4, 1999Date of Patent: May 3, 2005Inventors: Tomokazu Nagano, Ikue Kudo, Takao Kawamura, Mutsuo Taiji, Hiroshi Noguchi, Shunsuke Tani, Hiroo Maeda
-
Publication number: 20050019320Abstract: The present invention provides a novel therapeutic agent for a lifestyle-related disease or a cibophobia, which is superior in controlling food intake, and a screening method therefor. Specifically, a therapeutic agent for cibophobia comprising, as an active ingredient, a substance that suppresses expression or function of GPRC5D, GPCR expressed in hypothalamus, a therapeutic agent for a lifestyle-related disease comprising, as an active ingredient, a substance that enhances expression or function of the receptor, a screening system consisting of a series of coexpression systems of GPRC5D and various G proteins, and a screening method for a substance having a therapeutic activity against cibophobia or a lifestyle-related disease, which includes use of the screening system, are provided.Type: ApplicationFiled: December 27, 2002Publication date: January 27, 2005Inventors: Eiji Sugaru, Mitsugu Yamanaka, Junji Ichihara, Mutsuo Taiji
-
Patent number: 6800607Abstract: Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.Type: GrantFiled: August 29, 2002Date of Patent: October 5, 2004Assignee: LTT Bio-Pharma Co., Ltd.Inventors: Rie Igarashi, Yutaka Mizushima, Mutsuo Taiji, Chikao Nakayama, Hiroshi Noguchi
-
Patent number: 6689745Abstract: Agents for protecting or ameliorating pancreatic cells and tissues which contains as the active ingredient a neurotrophic factor such as BDNF. By using these drugs, degenerative dropout of pancreatic cells and pancreatic hypofunction caused by diabetes, acute/chronic pancreatitis, etc. can be efficaciously prevented and treated.Type: GrantFiled: October 16, 2001Date of Patent: February 10, 2004Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Yasushi Itakura, Mutsuo Taiji
-
Publication number: 20030073631Abstract: Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.Type: ApplicationFiled: August 29, 2002Publication date: April 17, 2003Inventors: Rie Igarashi, Yutaka Mizushima, Mutsuo Taiji, Chikao Nakayama, Hiroshi Noguchi
-
Publication number: 20030036512Abstract: Leptin resistance ameliorating agents comprising as the active ingredient a neurotrophic factor such as BDNF or a trk receptor ligand, namely, agents for ameliorating, treating or preventing hypertension, sterility, obesity, glucose metabolic disorders, ischemic diseases, growth hormone secretion insufficiency, growth hormone hyposecretion, immune function disorder, etc. caused by leptin resistance.Type: ApplicationFiled: September 6, 2002Publication date: February 20, 2003Inventors: Tsutomu Nakagawa, Mitsugu Yamanaka, Mutsuo Taiji
-
Publication number: 20030022840Abstract: Drugs for ameliorating, treating or preventing impaired glucose tolerance, which comprises as the active ingredient a neurotrophic factor such as BDNF or trk receptor agonist.Type: ApplicationFiled: August 16, 2002Publication date: January 30, 2003Inventors: Michiko Kishino, Mutsuo Taiji
-
Patent number: 6472366Abstract: The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.Type: GrantFiled: January 25, 2002Date of Patent: October 29, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Michiko Kishino, Chikao Nakayama, Mutsuo Taiji, Junji Ichihara, Hiroshi Noguchi
-
Publication number: 20020122829Abstract: The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.Type: ApplicationFiled: January 25, 2002Publication date: September 5, 2002Applicant: Sumitomo Pharmaceuticals Co., LimitedInventors: Michiko Kishino, Chikao Nakayama, Mutsuo Taiji, Junji Ichihara, Hiroshi Noguchi
-
Patent number: 6399658Abstract: L-ascorbic acid, L-ascorbic acid derivatives and salts thereof can reduce lactic acid levels in blood, and are useful for treating lactic acidosis and the like caused by administration of amoxapine, theophylline, metformin, phenformin, buformin, nalidixic acid, hopantenic acid, azidothymidine, dideoxycytidine, high caloric transfusion, propylene glycol, ethylene glycol, xylitol, lactose, sorbitol or the like.Type: GrantFiled: June 9, 1999Date of Patent: June 4, 2002Assignee: Sumitomo Pharmaceuticals Co., Ltd.Inventors: Hiroshi Noguchi, Mutsuo Taiji, Hiroshi Yamaga, Yasushi Itakura, Junji Ichihara
-
Patent number: 6391312Abstract: The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.Type: GrantFiled: July 23, 1999Date of Patent: May 21, 2002Assignee: Sumitomo Pharmaceuticals Co., LimitedInventors: Michiko Kishino, Chikao Nakayama, Mutsuo Taiji, Junji Ichihara, Hiroshi Noguchi